EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions

Xinyang Li, Meng Wu, Jie Lu, Jinming Yu, Dawei Chen

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024

DOI: 10.1016/j.bbcan.2024.189084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024. Verfasst von Xinyang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Weifang Medical University, Weifang, China; Department of Radiation Oncology and Shandong Provincial Key Laboratory of R…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 144 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has revolutionized cancer treatment. However, it's well-recognized that a considerable proportion of patients fail to benefit from immunotherapy, and to improve immunotherapy response is clinically urgent. Insufficient immune infiltration and immunosuppressive tumor microenvironments (TME) are main contributors to immunotherapy resistance. Thus sustaining functional self-renewal capacity for immune cells and subverting immune-suppressive signals are potential strategies for boosting the efficacy of immunotherapy. Interleukin-21 (IL-21), a crucial cytokine, which could enhance cytotoxic function of immune cells and reduces immunosuppressive cells enrichment in TME, shows promising orientations as an immunoadjuvant in tumor immunotherapy. This review focuses on IL-21 in cancer treatment, including function and mechanisms of IL-21, preclinical and clinical studies, and future directions for IL-21-assisted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansImmunotherapyInterleukinsAdjuvants, ImmunologicInterleukin-21

Stichwörter der Autor:innen

IL-21ImmunotherapyTumor microenvironment

Substanzen

Interleukin-21InterleukinsAdjuvants, ImmunologicAntineoplastic Agents

Autor:innen und Institutionen

  • School of Clinical Medicine, Weifang Medical University, Weifang, China; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong Fir…
  • Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Sh…

Förderung

  • National Natural Science Foundation of China
  • Shandong Province Natural Science Foundation

Zitieren

APA

Li, X., Wu, M., Lu, J., Yu, J., & Chen, D. (2024). Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2024.189084

Vancouver

Li X, Wu M, Lu J, Yu J, Chen D. Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024. doi:10.1016/j.bbcan.2024.189084

BibTeX
@article{Li2024,
  author = {Li, Xinyang and Wu, Meng and Lu, Jie and Yu, Jinming and Chen, Dawei},
  title = {Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2024},
  doi = {10.1016/j.bbcan.2024.189084}
}
Kostenlos starten →